The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Open accessAbstract
Tamoxifen has been the mainstay of hormonal therapy in both early and advanced breast cancer patients for approximately three decades. The availability of novel compounds such as aromatase inhibitors (AIs) and fulvestrant, with different mechanism of action, is changing the scenario of endocrine treatment of postmenopausal breast cancer patients. In this review article, we have summarized the current knowledge of the mechanisms of resistance to endocrine therapy, in order to derive information that might be useful for therapeutic intervention. We propose that resistance to endocrine therapy is a progressive, step-wise phenomenon induced by the selective pressure of hormonal agents, which leads breast cancer cells from an estrogen-dependent, responsive to endocrine manipulation phenotype to a non-responsive phenotype, and eventually to an estrogen-independent phenotype. In particular, evidence suggests for each ‘action’ introduced to block estrogen stimulation of breast cancer cells (i.e. treatment with anti-estrogen), there are one or more corresponding ‘reactions’ that tumor cells can use to escape our attempts to block their growth: estrogen hypersensitivity associated with increased transcriptional activity of estrogen receptor α (ERα) and/or increased non-genomic activity of ERα, estrogen supersensitivity, increased growth factor signaling, suppression of ERα expression and finally estrogen independence. Activation of growth factor signaling is involved in each step of this phenomenon, and might ultimately substitute estrogen in sustaining the growth and the survival of breast cancer cells. In this respect, results of pre-clinical and clinical studies with AIs, fulvestrant and signaling inhibitors sustain this hypothesis. More importantly, the knowledge of the mechanisms involved in the resistance of breast cancer cells to endocrine therapy offers potential for novel therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wong, C.-W., McNally, C., Nickbarg, E., Komm, B. S., & Cheskis, B. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192569699 · Cited by 324
RetractedBiochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
HOSKINS, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Self-citationHörlein, A. J., Näär, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Söderström, M., Glass, C. K., et al. (1995) · Nature · doi:10.1038/377397a0 · Cited by 2,034
Molecular and cellular endocrinology
(1995) · Journal of Endocrinology · doi:10.1677/joe.0.147so19 · Cited by 1,991
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A transcriptional co-repressor that interacts with nuclear hormone receptors
Chen, J. D., & Evans, R. M. (1995) · Nature · doi:10.1038/377454a0 · Cited by 1,763
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
The Journal of Steroid Biochemistry and Molecular Biology
(2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(11)00143-9 · Cited by 1,234
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Hall, J. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7179 · Cited by 1,075
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
Rountree, M. R., Bachman, K. E., & Baylin, S. B. (2000) · Nature Genetics · doi:10.1038/77023 · Cited by 1,052
Breast Cancer Research and Treatment
Alexander, M. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006151427889 · Cited by 997
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Bunone, G., Briand, P. A., Miksicek, R. J., & Picard, D. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00571.x · Cited by 986
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 959
Robertson, K. D., Ait-Si-Ali, S., Yokochi, T., Wade, P. A., Jones, P. L., & Wolffe, A. P. (2000) · Nature Genetics · doi:10.1038/77124 · Cited by 942
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Frasor, J., Danes, J. M., Komm, B., Chang, K. C. N., Lyttle, C. R., & Katzenellenbogen, B. S. (2003) · Endocrinology · doi:10.1210/en.2003-0567 · Cited by 876
Estrogen receptor pathways to AP-1
Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., & Webb, P. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 870
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Bardou, V.-J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.099 · Cited by 752
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660 · cited 2×
“In addition, it has been shown that tamoxifen interacts with co-repressors when bound to ER, and that this mechanism is involved in the suppression of transcription (Lavinsky et al .”
BackgroundMechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 642
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Pietras, R. J., Arboleda, J., Dm, R., Wongvipat, N., Pegram, M. D., Ramos, L., Cm, G., Mg, P., Sliwkowski, M. X., & Dj, S. (1995) · PubMed · Cited by 603
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
McDonnell, D. P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.6.659 · Cited by 526
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
The SRC family of nuclear receptor coactivators
Leo, C., & Chen, J. D. (2000) · Gene · doi:10.1016/s0378-1119(00)00024-x · Cited by 520
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
Ottaviano, Y. L., Issa, J. J., Parl, F. F., Smith, H. S., Baylin, S. B., & Davidson, N. E. (1994) · PubMed · Cited by 481
Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway
Kahlert, S., Nuedling, S., van Eickels, M., Vetter, H., Meyer, R., & Grohé, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910345199 · Cited by 474
Proximal Events in Signaling by Plasma Membrane Estrogen Receptors
Razandi, M., Pedram, A., Park, S. T., & Levin, E. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205692200 · Cited by 473
Osborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., & Osborne, C. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031212 · Cited by 462
AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor
Font de Mora, J., & Brown, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5041-5047.2000 · Cited by 432
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Cancer Chemotherapy and Pharmacology
(2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/280.1432-0843 · Cited by 430
Howell, A., Robertson, J. F. R., Abram, P., Lichinitser, M. R., Elledge, R., Bajetta, E., Watanabe, T., Morris, C., Webster, A., Dimery, I., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.112 · Cited by 421
Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions
Safe, S. (2001) · Vitamins & Hormones · doi:10.1016/s0083-6729(01)62006-5 · Cited by 418
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
(1988) · PubMed · Cited by 416
Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2702 · Cited by 407
Self-citationSong, R. X.-D., McPherson, R. A., Adam, L., Bao, Y., Shupnik, M., Kumar, R., & Santen, R. J. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0748 · Cited by 407
Estrogen Receptor Mutations in Human Disease
Herynk, M. H., & Fuqua, S. A. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0010 · Cited by 400
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600126 · Cited by 394
Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379
TRANSCRIPTION ACTIVATION BY ESTROGEN AND PROGESTERONE RECEPTORS
Gronemeyer, H. (1991) · Annual Review of Genetics · doi:10.1146/annurev.ge.25.120191.000513 · Cited by 378
Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3357 · Cited by 365
Kurokawa, H., Lenferink, A. E. G., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., & Arteaga, C. L. (2000) · PubMed · Cited by 363
Estrogen receptor β acts as a dominant regulator of estrogen signaling
Pettersson, K., Delaunay, F., & Gustafsson, J.-Å. (2000) · Oncogene · doi:10.1038/sj.onc.1203828 · Cited by 362
Sun, M., Paciga, J. E., Feldman, R. I., Yuan, Z., Coppola, D., Lu, Y., Shelley, S. A., Nicosia, S. V., & Cheng, J. Q. (2001) · PubMed · Cited by 360
Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications
Osborne, C. K., & Schiff, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.036 · Cited by 351
Song, R. X., Barnes, C. J., Zhang, Z., Bao, Y., Kumar, R., & Santen, R. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308334100 · Cited by 349
pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167
Joel, P. B., Smith, J., Sturgill, T. W., Fisher, T. L., Blenis, J., & Lannigan, D. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.1978 · Cited by 345
Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor Receptor
Levin, E. R. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0368 · Cited by 329
Aromatase inhibitors for breast cancer: lessons from the laboratory
Johnston, S. R. D., & Dowsett, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1211 · Cited by 326
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000115858.45890.53 · Cited by 315
Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.029 · Cited by 310
Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
Masamura, S. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.10.2918 · Cited by 307
Schiff, R., Massarweh, S. A., Shou, J., & Osborne, C. K. (2003) · PubMed · Cited by 304
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Martin, L.-A., Farmer, I., Johnston, S. R. D., Ali, S., Marshall, C., & Dowsett, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305226200 · Cited by 295
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Self-citationMcClelland, R. A., Barrow, D., Madden, T., Dutkowski, C. M., Pamment, J., Knowlden, J. M., Gee, J. M. W., & Nicholson, R. I. (2001) · Endocrinology · doi:10.1210/en.142.7.2776 · Cited by 258
Ray, P., Ghosh, S. K., Zhang, D.-H., & Ray, A. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00487-0 · Cited by 256
Arpino, G., Green, S. J., Allred, D. C., Lew, D., Martino, S., Osborne, C. K., & Elledge, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0110 · Cited by 255
Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., & Nicholson, R. I. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4<247::aid-ijc1042>3.0.co;2-s · Cited by 249
Gottardis, M. M., Jiang, S.-T., Jeng, M., & Jordan, V. C. (1989) · PubMed · Cited by 247
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
Wegman, P., Vainikka, L., Stål, O., Nordenskjöld, B., Skoog, L., Rutqvist, L.-E., & Wingren, S. (2005) · Breast Cancer Research · doi:10.1186/bcr993 · Cited by 243
Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.
Speirs, V., Malone, C. M., Walton, D. S., Kerin, M. J., & Atkin, S. L. (1999) · PubMed · Cited by 237
Osborne, C. K., Coronado, E., Allred, D. C., Wiebe, V., & DeGregorio, M. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.20.1477 · Cited by 235
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
Fuqua, S. A. W., Wiltschke, C., ZHANG, Q. X., Borg, Å., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S. G., Mohsin, S. K., O'Connell, P., et al. (2000) · PubMed · Cited by 234
Cui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G. B., & Lee, A. V. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0318 · Cited by 233
Yang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., & Davidson, N. E. (2000) · PubMed · Cited by 228
Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells
Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., & El-Ashry, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.8.0678 · Cited by 226
Cariou, S., Donovan, J. C. H., Flanagan, W. M., Milic, A., Bhattacharya, N., & Slingerland, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160016897 · Cited by 224
Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., & Miles, D. W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690196 · Cited by 220
Estrogen receptor: current understanding of its activation and modulation.
Osborne, C. K., Schiff, R., Fuqua, S. A. W., & Shou, J. (2001) · PubMed · Cited by 194
Polychronis, A., Sinnett, H. D., Hadjiminas, D., Singhal, H., Mansi, J. L., Shivapatham, D., Shousha, S., Jiang, J., Peston, D., Barrett, N., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70176-5 · Cited by 194
Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3471 · Cited by 180
Dowsett, M., Harper-Wynne, C. L., Boeddinghaus, I., Salter, J., Hills, M., Dixon, M., Ebbs, S. R., Gui, G. P., Sacks, N., & Smith, I. E. (2001) · PubMed · Cited by 172
Gee, J. M. W., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D., Knowlden, J. M., McClelland, R. A., Jordan, N., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2003-0705 · Cited by 170
Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells
Hutcheson, I. R., Knowlden, J. M., Madden, T.-A., Barrow, D., Gee, J. M. W., Wakeling, A. E., & Nicholson, R. I. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025484908380 · Cited by 169
Liu, Y., El-Ashry, D., Chen, D., Ding, I. Y. F., & Kern, F. G. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00665783 · Cited by 163
Chan, C. M. W., Martin, L., Johnston, S. R. D., Ali, S., & Dowsett, M. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00074-2 · Cited by 149
Chung, Y., Sheu, M., Yang, S., Lin, C., & Yen, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1614 · Cited by 142
Macaluso, M., Cinti, C., Russo, G. M., Russo, A. D., & Giordano, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206578 · Cited by 137
Self-citationLong, B. J., Jelovac, D., Handratta, V. D., Thiantanawat, A., Macpherson, N. A., Ragaz, J., Goloubeva, O. G., & Brodie, A. M. H. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh076 · Cited by 137
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., & Wakeling, A. E. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685924 · Cited by 133
Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells
Jordan, N., Gee, J. M. W., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000041623.21338.47 · Cited by 127
Fan, M., Bigsby, R. M., & Nephew, K. P. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0323 · Cited by 127
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Harvey, H. A., Chaudri‐Ross, H. A., Brady, C., Wyld, P. J., & Carney, W. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.098 · Cited by 124
Knoop, A. S., Bentzen, S. M., Nielsen, M. M., Rasmussen, B., & Rose, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3376 · Cited by 122
Tang, C. K., Pérez, C., Grunt, T. W., Waibel, C., Cho, C., & Lupu, R. (1996) · PubMed · Cited by 120
Aromatase inhibitors in breast cancer.
Lønning, P. E. (2004) · Endocrine Related Cancer · doi:10.1677/erc.0.0110179 · Cited by 115
Paridaens, R., Therasse, P., Dirix, L. Y., Beex, L. V. A. M., Piccart, M. J., Cameron, D., Cufer, T., Roozendaal, K. J., Nooij, M. A., & Mattiacci, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.515 · Cited by 114
Atlas, E., Cardillo, M., Mehmi, I., Zahedkargaran, H., Tang, C. K., & Lupu, R. (2003) · PubMed · Cited by 113
Epidermal growth factor-related peptides in the pathogenesis of human breast cancer
Normanno, N., Ciardiello, F., Brandt, R., & Salomon, D. S. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666178 · Cited by 110
Self-citationEl‐Ashry, D., Miller, D. L., Kharbanda, S., Lippman, M. E., & Kern, F. G. (1997) · Oncogene · doi:10.1038/sj.onc.1201198 · Cited by 104
Blackwell, K., Kaplan, E., Franco, S. X., Marcom, P. K., Maleski, J. E., Sorensen, M. J., & Berger, M. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3006 · Cited by 96
Yue, W., Wang, J., Conaway, M. R., Li, Y., & Santen, R. J. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00366-2 · Cited by 91
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
Ellis, M. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-20 · Cited by 84
Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma.
Weigel, R. J., & deConinck, E. C. (1993) · PubMed · Cited by 83
Stål, O., Borg, Å., Fernö, M., Källström, A.-C., Malmström, P., & Nordenskjöld, B. A. (2000) · Annals of Oncology · doi:10.1023/a:1008313310474 · Cited by 82
Davis, T. A., Kennedy, C. J., Chiew, Y.-E., Clarke, C. L., & DeFazio, A. (2000) · PubMed · Cited by 81
Regulation of estrogen receptor-alpha gene expression by epidermal growth factor
Stoica, A., Saceda, M., Doraiswamy, V., Coleman, C., & Martin, M. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650371 · Cited by 81
Johnston, S. R. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.889s.11.2 · Cited by 75
Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)
Argiris, A. E., Wang, C.-X., Whalen, S. G., & DiGiovanna, M. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1060-02 · Cited by 73
Gradishar, W. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-378 · Cited by 67
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
Strasser‐Weippl, K., & Goss, P. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.038 · Cited by 66
Long, B. J., Jelovac, D., Thiantanawat, A., & Brodie, A. M. H. (2002) · PubMed · Cited by 63
McDonnell, D. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.871s.11.2 · Cited by 62
Vergote, I. B., Robertson, J. F. R., Kleeberg, U. R., Burton, G., Osborne, C. K., & Mauriac, L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023983032625 · Cited by 61
Long-Term Exposure to Tamoxifen Induces Hypersensitivity to Estradiol
Berstein, L. M., Wang, J., Zheng, H., Yue, W., Conaway, M. R., & Santen, R. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0433-03 · Cited by 57
Therapeutic Observations in MCF-7 Aromatase Xenografts
Brodie, A. M. H., Jelovac, D., Macedo, L. F., Sabnis, G. J., Tilghman, S. L., & Goloubeva, O. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.884s.11.2 · Cited by 51
Stoica, A., Saceda, M., Fakhro, A., Solomon, H. B., Fenster, B. D., & Martin, M. B. (1997) · Endocrinology · doi:10.1210/endo.138.4.5074 · Cited by 50
Santen, R. J., Song, R., Zhang, Z., Kumar, R., Jeng, M. H., Masamura, S., Yue, W., & Berstein, L. M. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100111 · Cited by 48
Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma
Ropero, S., Menéndez, J. A., Vázquez‐Martín, A., Montero, S., Cortés-Funes, H., & Colomer, R. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000032981.20384.c6 · Cited by 47
Robertson, F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I. B., Gertler, S., et al. (2004) · The Women s Oncology Review · doi:10.3109/14733400410001728474 · Cited by 39
Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells
Song, R., Santen, R. J., Kumar, R., Adam, L., Jeng, M. H., Masamura, S., & Yue, W. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00093-x · Cited by 38
Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer
Parl, F. F. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500201 · Cited by 28
Cappelletti, V., Celio, L., Bajetta, E., Allevi, A., Longarini, R., Miodini, P., Villa, R., Fabbri, A., Mariani, L., Giovanazzi, R., et al. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00822 · Cited by 26
Piccart, M. J., Parker, L. M., & Pritchard, K. I. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg290 · Cited by 23
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen
Lipton, A., Mouridsen, H. T., Ali, S.-A. M., et al. (2001) · Breast Diseases A Year Book Quarterly · Cited by 22
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
Coronado, E. B., Hilsenbeck, S. G., Wakeling, A. E., et al. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050111 · Cited by 9
Cited by
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Calcium and cancer: targeting Ca2+ transport
Monteith, G. R., McAndrew, D., Faddy, H. M., & Roberts-Thomson, S. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2171 · Cited by 676
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P. (2011) · Oncogene · doi:10.1038/onc.2010.487 · Cited by 342
miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy
Garofalo, M., Quintavalle, C., Romano, G., M. Croce, C., & Condorelli, G. (2012) · Current Molecular Medicine · doi:10.2174/156652412798376170 · Cited by 331
Metadata
- Authors
- Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2005-12
- Volume
- 12
- Issue
- 4
- Pages
- 721-747
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2125713798
- Cited by
- 286
- References
- 143
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.